Oil-in-water method for making polymeric implants containing a hypotensive lipid
    2.
    发明授权
    Oil-in-water method for making polymeric implants containing a hypotensive lipid 有权
    用于制造含有低血压脂质的聚合物植入物的水包油法

    公开(公告)号:US08722097B2

    公开(公告)日:2014-05-13

    申请号:US11371118

    申请日:2006-03-08

    IPC分类号: A61K9/50 B01J13/02 B01J13/04

    摘要: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.

    摘要翻译: 生物相容的微粒包括眼科活性的环状脂质组分和可生物降解的聚合物,当放置在结膜下空间中时,有效地促进环状脂质成分延长眼睛部分的时间。 环状脂质组分可与可生物降解的聚合物基质相结合,例如两种可生物降解聚合物的基质。 或者,环状脂质组分可以被聚合物组分包封。 本发明的微粒包括水包油乳化微粒。 结膜下施用的微粒可用于治疗或减少眼部疾病如青光眼或年龄相关性黄斑变性的至少一种症状。

    Therapeutic Lacrimal Canalicular Inserts And Related Methods
    3.
    发明申请
    Therapeutic Lacrimal Canalicular Inserts And Related Methods 审中-公开
    治疗性泪腺插管及相关方法

    公开(公告)号:US20080038317A1

    公开(公告)日:2008-02-14

    申请号:US11572097

    申请日:2005-09-07

    IPC分类号: A61F2/14 A61K38/12 A61P27/00

    CPC分类号: A61K9/0051 A61F9/00772

    摘要: Lacrimal canalicular inserts include a polymeric component and a therapeutic component. The therapeutic component is released from the inserts for extended periods of time, such as for more than about 2 weeks after placement in a lacrimal canaliculus of an individual. The polymeric component may include one or more non-biodegradable polymers, one or more biodegradable polymers, or combinations thereof. The therapeutic component may include one or more therapeutic agents. Therapeutically effective amounts of the therapeutic component are released from the insert and provide sustained drug delivery to the eye and/or the nasolacrimal system of the individual.

    摘要翻译: 泪小管插入物包括聚合物组分和治疗组分。 治疗组分从插入物中延长的时间段释放,例如放置在个体的泪小管中超过约2周。 聚合物组分可以包括一种或多种不可生物降解的聚合物,一种或多种可生物降解的聚合物,或其组合。 治疗组分可以包括一种或多种治疗剂。 治疗成分的治疗有效量从插入物释放并提供持续的药物递送到个体的眼睛和/或鼻泪管系统。